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Abstract
Background Evaluation of antibiotic-impregnated (AI)
and ionized silver particle coated external ventricular
drainage catheters (EVD) in patients with subarachnoid
(SAH) or intracranial hemorrhage (ICH).
Methods Between February 2011 and June 2012, 40
patients with acute hydrocephalus due to SAH, ICH or
intraventricular hemorrhage were enrolled in a prospective,
randomized, mono-center pilot study. Primary endpoints
were defined as: number of events of cerebrospinal fluid
(CSF) infections. Secondary endpoints were defined as:
neurosurgical complications following the placement of the
EVD, number of revisions of EVD catheters, and cost
effectiveness.
Results Sixty-one EVD placements in 40 patients, 32
antibiotic-coated (Bactiseal), 29 silver-bearing catheters
(VentriGuard), have been performed. Confirmed or high
suspicion of CSF infections occurred in 11 out of 61 events
(confirmed infection: p = 0.71, probable infection:
p = 0.90). Revisions of EVD were needed in 13 cases
(22 %) due to CSF infection, dysfunction, impaired heal-
ing, or malplacement (p = 0.37).
Conclusion Regarding CSF infection rate and dysfunc-
tion, no statistical significant differences between the two
EVD catheters Bactiseal versus VentriGuard were
found. The silver-bearing catheter might offer a safe and
cost-conscious alternative to the AI catheter.
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Introduction
The placement of external ventricular drainage catheters
(EVD) belongs to the standard surgical procedures in
managing acute hydrocephalus [1–3]. Perioperative com-
plications, however, such as infections, intracranial
hemorrhages (ICHs), or catheter malplacements are well
known [3, 4]. Several previous trials have focused on
catheter related cerebrospinal fluid infections (CSF) and
bacterial colonization due to different types of EVDs
(0–27 %), [4–7].
Zabramski et al. [6] and Abba et al. [7] reported about
the efficacy of EVD polyethylene catheters impregnated
with rifampicin and clindamycin versus non-coated cathe-
ters. Antibiotic-coated catheters (AI) have shown
decreased colonization and CSF infection rates [6, 7].
Recently, however, Pople et al. presented an international,
prospective, randomized, open label trial indicating low
infection rates in both study arms, i.e., AI catheters
(17.6 %) versus standard EVD (20.4 %). Furthermore, AI
catheters were not associated with a lower infection rate
compared to non-coated catheters [8].
In retrospective trials, Lackner and Fichtner et al. ana-
lyzed the efficacy of the silver-impregnated EVD catheters
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(SI) versus non-coated EVD. Both studies showed a sig-
nificant reduction of bacterial colonization and CSF
infection rate in the SI group (18.9 %) [9, 10]. Keong et al.
reported in a double-blinded, prospective, randomized
controlled trial a significant difference in infection rate
between the two study arms (non-coated: 21.4 % vs. silver-
bearing: 12.3 %, p = 0.04). They concluded that silver-
bearing catheters reduce the risk of CSF infections [11].
At the University Hospital Zurich, Department of Neu-
rosurgery, a prospective, randomized, mono-center pilot
study was established in order to evaluate antibiotic-
impregnated (AI) versus ionized silver particle coated
EVDs with regard to the incidence of CSF infections and
neurosurgical complications following the placement of the
EVD, as well as to the number of revisions of EVD cath-
eters and the cost effectiveness.
Patients and Methods
From February 2011 to June 2012 a mono-centric, prospective
randomized controlled trial to evaluate complications with AI
versus silver-ionized EVD catheters was performed at the
Department of Neurosurgery of the University Hospital
Zurich (approved by the ethics committee: KEK-ZH-Nr:
2010-214). Written informed consent was obtained from all
participating patients. Primary endpoints were defined as:
number of events of CSF infections. Secondary endpoints
were defined as: neurosurgical complications following the
placement of the EVD, number of revisions of EVD catheters,
and cost effectiveness.
Study Population
Patients between 18 and 80 years, admitted to the
emergency unit with the initial diagnosis of subarachnoid
hemorrhage (SAH), intracranial hemorrhage (ICH) or
intraventricular hemorrhage, and occlusive hydrocephalus
were randomized and enrolled. Exclusion criteria were:
prior infections (meningitis, ventriculitis, sepsis, bacteri-
emia, chronic infection disease, or skin infection close
to the implantation site), allergic reactions to rifampicin
or clindamycin, pregnancy or residency outside
Switzerland.
The two catheters examined were the AI ventricular
drainage catheter (12 Charrier, Rifampicin/Clindamycin;
Bactiseal, Codman and Shurtleff, Johnson & Johnson,
Ranyham, Massachusetts) and the silver-ionized (SI) ven-
tricular drainage catheter (8.5 French, ionized, silver-
bearing; VentriGuard Neuromedex, Zollikon Zurich,
Switzerland).
Treatment
After randomization EVDs were placed according to a
standardized insertion protocol [3]. CSF samples were
collected during insertion and every third day thereafter
and analyzed for leukocytes and microorganisms. Clinical
signs of infection, such as fever, change of vigilance, and
local wound control were documented. Detected microor-
ganisms in the CSF and on the catheters were identified by
direct microscopy and/or cultures performed by a blinded
microbiologist (Department of Microbiology, University
Hospital Zurich). CSF findings were categorized as fol-
lows: CSF infection was assigned to be ‘‘confirmed’’ if the
leukocyte count per visual field was >200 and clinical
signs of CSF infection were present and microorganisms
were identified in the CSF and/or the catheter tip. CSF
infection was categorized as ‘‘probable’’ if the leucokyte
count per visual field was >100 and/or one but not all of
the characteristics above were present. Primary endpoints
were the events of CSF and EVD infections. Secondary
endpoints were surgical complications (impaired wound
healing/CSF leakage, hemorrhage in trajectory, or mal-
placement), changes of EVD, overall costs of EVD, and
identifying most common microorganisms in the CSF in
cases of confirmed infection.
Statistical Analysis
We present numbers of patients and percentages of total for
categorical variables, and continuous variables as
mean ± standard deviation (SD). For the univariate com-
parison of primary and secondary outcomes in the
comparison groups AI-EVD and SI-EVD, we used v2 tests.
Significance level a was set at 5 %. All analyses were
performed with R (R Development Core Team 2013. R: A
language and environment for statistical computing.
R Foundation for Statistical Computing, Vienna, Austria).
Results
From February 2011 to June 2012 27 female (67 %) and 13
(33 %) male patients, with the mean age of 56.5 years
(mean ± SD 13.2) were enrolled. 32 patients suffered from
SAH (80 %), 8 from ICH (20 %). Twenty-eight patients
with ruptured aneurysms were treated with clipping (8
patients) or coiling (20 patients), in 4 patients no aneurysm
was detected in the angiography. In seven patients an ICH
and in one patient an arteriovenous malformations was
documented. Overall, 61 EVD catheters (32 Bactiseal vs.
29 VentriGuard) were placed in 40 patients. Mean time
in situ was 15 days (range 3–30 days). Duration of stay in
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the ICU was 27.6 ± 14.8 (mean ± SD). The overall
mortality rate was 16 % (Tables 1, 2).
Primary Endpoint
CSF infections (including categories ‘‘confirmed’’ and
‘‘probable’’) occurred in a total of 11 out of 61 events
(18 %), 3 confirmed with AI and 3 confirmed with SI
catheters (10 %, p = 0.71), 2 probable with AI and 3
probable with SI catheters (8 %, p = 0.90). Median onset
of infection was day 11 (range 5–30 days). In confirmed
infections the microbiological examinations revealed
Staphylococcus coagulase negative (in total 4 events; 2
events with AI and 2 events with SI catheters) and Esch-
erichia coli (in total 2 events; 1 with AI and with SI
catheters) (Table 3).
Secondary Endpoint
Overall revisions of EVD were necessary in 13 cases
(22 %, p = 0.37). In three patients (a hemorrhage in the
trajectory line (2 patients with AI, 1 with SI catheters, 5 %,
p = 0.51) and in two patients a malplacement of the EVD
(with AI catheter) occurred (3 %, p = 0.93). No allergic
reactions occurred in either of the groups. In 12 patients
(30 %) ventricular peritoneal shunt placement (VP-shunt)
was performed later on. Overall costs of EVD devices were
20.345 USD (5.103 USD higher in the AI group) (Table 4).
Discussion
The present pilot study in 40 patients revealed equal rates
of CSF infection in patients with AI compared to patients
with SI catheters. With six (10 %) confirmed and five
(8 %) probable infections, the overall infection rate was
comparable with previous published data [3, 4, 6, 8, 9, 11].
Lozier and colleagues [12, 13] analyzed a cumulative CSF
infection rate of 8.8 % (range 2.2–21.9 %) in 23 studies. A
very low proven infection rate (2.5–2.8 %) was recently
reported by Pople et al. [8], though the rate was influenced
by abundant use of antibiotics and based on primary EVD
placements only. The silver trial of Keong et al. [11] with
an infection rate of 12.3 % showed more comprehensible
results. Our patient population represented a group of most
severely ill patients with long ICU stays, consecutive high
risks of infections and complications as well as revisionary
and secondary EVD placements. Antibiotics were used
only if systemic infections or proven, respectively, proba-
ble CSF infections were detected. Onset of infection or
length of implantation did not influence the infection rate
in our population. However, data on the comparison of AI
versus SI catheters have not been published yet.
Bacterial resistance and allergic reactions, especially
seen in colonization with Staphylococcus aureus in rif-
ampicin and clindamycin coated catheters, are still under
discussion in the literature [4]. Furthermore, observations
of neurotoxicity of silver ions have been described [14].
However, no allergic reactions were reported in either of
the groups and no evident neurotoxic side effects of silver
particles were observed in the group with SI catheters.
The overall surgical complication rate of 7 % (Table 1)
fits in the lower median as reported in literature (range
1–33 %) [3, 15, 16]. Following a retrospective evaluation
of surgical complication rates at the Department of Neu-
rosurgery of the University Hospital Zurich [3], a
standardized surgical and handling protocol was estab-
lished which enabled to reduce the surgical complication
rate from 10 to 7 %. Therefore, standardized surgical
protocols and thoroughly maintained EVD devices improve
the surgical and overall complication rate and should be
established in every center [3, 5, 8, 11–13, 15, 16].
Handling and maintenance of AI or SI catheters in ICU
were standardized and showed no difference in either
Table 1 Patient characteristics,
severity measures, and outcome
scores
SD standard deviation, y years,
ICU intensive care unit,
SAH subarachnoid hemorrhage,
AVM arterio-venous
malformation, ICH intracranial
hemorrhage
Variables Category Percentage
Gender Male: n = 13 33
Female: n = 27 67
Age (mean ± SD, y) 56.5 ± 13.2
Admission disease SAH: n = 32 80
AVM: n = 1 3
ICH: n = 7 17
Days in ICU (mean ± SD) 27.6 ± 14.8
Glasgow outcome scale 1: n = 6 15
2: n = 0 0
3: n = 3 7.5
4: n = 9 22.5
5: n = 22 55
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Table 2 Scores by reason for
admission
WFNS World Federation of
Neurosurgeons, GCS Glasgow
coma scale
Reason for admission
SAH (n = 32) AVM (n = 1) ICH (n = 7)
WFNS
1 4
2 9
3 3
4 5
5 11
Hunt + Hess
1 2
2 15
3 5
4 5
5 5
Fisher
1 0
2 1
3 14
4 16
GCS
3 1
8–3 1 4
15–8 2
Table 3 Primary endpoints: CSF infections
Characteristics Overall (n) AI-EVD (n) SI-EVD (n) p*
EVD 61 32 29 –
CSF infection 11 5 6 0.92
Confirmed inf. 6 3 3 0.71
Probable inf. 5 2 3 0.90
Onset of CSF inf. 11 (d, median) – –
n number, AI-EVD antibiotic external ventricular drainage catheter, SI-EVD silver-ionized external ventricular drainage catheter, CSF cere-
brospinal fluid, inf infection, d day
* p value from v2 test
Table 4 Secondary endpoints: revision, surgical complications, costs
Characteristics Overall (n) AI-EVD (n) SI-EVD (n) p*
Revision 13 5 8 0.37
Malplacement 2 1 1 0.51
Hemorrhage 3 2 1 0.93
Costs (USD) 20.345 – –
Difference in costs (USD) +5.103
n number, AI-EVD antibiotic external ventricular drainage catheter, SI-EVD silver-ionized external ventricular drainage catheter, USD US Dollar
* p value from v2 test
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group. From an economic and diagnose related group point
of view, it seems that the SI catheter is more cost-efficient
than the AI catheter (Table 4).
Although the caseload of this prospective, randomized,
mono-center pilot study is limited, our preliminary data
suggest that there is no difference between the AI or SI
catheters in this selected patient population.
Conclusion
This is the first prospective, randomized, mono-center pilot
study to evaluate the incidence of CSF infections after
placement of AI versus silver-ionized ventricular drainage
catheters. No significant differences between the two EVD
catheters, especially regarding the CSF infection rate, were
found. The silver-ionized catheter might be a safe and cost-
conscious alternative to the AI catheter. To underline these
observations, further multicenter randomized trials would
be needed.
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